Preliminary results show that, while Lagevrio hastened the time to recovery from COVID-19 by around six days, it was no better than placebo at keeping patients out of hospital.

Merck & Co has said it will ask the EMA’s human medicines committee (CHMP) to look again at a decision not to recommend approval of its antiviral Lagevrio for treating some people with COVID-19.

Cat owners in China desperate to save their beloved cats are using human COVID-19 drugs like Merck’s Lagevrio to treat Feline Infectious Peritonitis (FIP)—a deadly disease in cats that earlier ...